Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Lexicon Pharmaceuticals (LXRX) PT Lowered to $6 at H.C. Wainwright
November 1, 2024 6:39 AM EDT(Updated - November 1, 2024 6:40 AM EDT)
H.C. Wainwright analyst Joseph Pantginis lowered the price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $6.00 (from $10.00) while maintaining a Buy rating.
The analyst commented: "Yesterday, the AdCom for sotagliflozin in T1D+CKD was... More
Lexicon Pharma (LXRX) Halted, News Pending
October 31, 2024 7:01 AM EDTLexicon Pharma (NASDAQ: LXRX) Halted, News Pending
... More


